miR‐205‐3p promotes proliferation and reduces apoptosis of breast cancer MCF‐7 cells and is associated with poor prognosis of breast cancer patients

Abstract

Background To study the expression of microribonucleic acid (miR)‐205 in breast cancer and its effects on the proliferation and apoptosis of breast cancer cells. Methods Breast cancer cell line MCF‐7 cells with stable expression of miR‐205‐3p were constructed. Cell proliferation, invasion, and apoptosis were detected via MTT assay, transwell assay, and flow cytometry, respectively. The expressions of Ezrin, LaminA/C, cleaved caspase‐3, Bcl‐2, and Bax were detected via Western blotting. The expressions of miR‐205‐3p in breast cancer tissues and para‐carcinoma tissues were detected via quantitative PCR (qPCR). Results In transfection group, cell proliferation and invasion capacities were increased significantly (P < 0.01), but apoptotic cells were significantly reduced (P < 0.01). In addition, the expressions of Ezrin, LaminA/C, and cleaved caspase‐3 in the transfection group were significantly decreased (P < 0.01), but the Bcl‐2/Bax ratio was significantly increased (P < 0.01). The miR‐205‐3p expression in tumor tissues of breast cancer patients was significantly higher than that in para‐carcinoma tissue, but Ezrin, LaminA/C, and cleaved caspase‐3 expressions in tumor tissues were remarkably declined (P < 0.01), while the Bcl‐2/Bax ratio was remarkably increased (P < 0.01). Moreover, the 5‐year survival of patients with high expression of miR‐205‐3p was significantly shorter than patients with normal or low expression (P < 0.01). Conclusion Highly expressed miR‐205‐3p can promote the proliferation and invasion and reduce the apoptosis of breast cancer cells, and the high expression of miR‐205‐3p can significantly reduce the survival time of patients.

Berberine Inhibits the Expression of SCT through miR‐214‐3p Stimulation in Breast Cancer Cells

“…In our investigation, the focus was to seek the key ncRNA and its target pathway in the antibreast cancer mechanism of BBR. We first listed a panel of 18 miRNAs [6][7][8][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] and 9 lncRNAs [9,10,15,[29][30][31][32][33][34] that were previously reported to be related with breast cancer, and we found that BBR illustrated a dosage-dependent pattern in the stimulation to miR-214-3p in both MCF-7 and MDA-MB-231 cells. miRNA is one of the important regulators that act as a posttranscriptional suppression officer.…”

“…In this study, we first made a panel of 18 miRNAs [6][7][8][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] and 9 lncRNAs [9,10,15,[29][30][31][32][33][34] that were previously reported to be related with breast cancer. en, based on a series of tests, we identified miR-214-3p as the crucial miRNA mediating in the antitumor effects of BBR in MCF-7 and MDA-MB-231 breast cancer cells.…”

MicroRNA‑623 inhibits tumor progression and is a predictor of poor prognosis of breast cancer

“…For example, overexpressed miR-675 in non-small cell lung cancer promotes the progression of the disease by activating the NF-κB signaling pathway (30). A number of miRNAs, such as miR-145-5p, miR-940, and miR-205-3p (19,31,32), which serve roles in the progression of breast cancer have been considered as potential biomarkers for breast cancer. Previously, miR-623 was reported to be dysregulated in breast cancer (33) and to serve roles in various cancers (20)(21)(22).…”

Ezrin expression in female reproductive tissues: A review of regulation and pathophysiological implications

“…Studies have confirmed that an increasing number of microRNAs and long non-coding RNAs are involved in the post-transcriptional regulation of ezrin, and cyclic RNAs have also been reported to play biological roles by binding to ezrin. The major microRNAs of ezrin include: miR-183 ( Zhang and Wang, 2019 ; Cao et al, 2020 ), miR-200b ( Yuan et al, 2020 ), miR-96 ( Yao et al, 2018 ; Mao et al, 2019 ), miR-211 ( Pei et al, 2019 ; Naso et al, 2020 ), miR-148b ( Sun et al, 2018 ), miR-205-3p ( Qiu et al, 2019 ), miR-25-3p ( Rao et al, 2020 ), miR-335-5p ( Tamanini et al, 2021 ), miR-462-731 ( He et al, 2022 ), miR-802 ( Ge et al, 2022 ), miR-204-5p ( Jiang et al, 2021 ); the long non-coding RNAs (lncRNAs) and cirRNAs include: lncRNA EZR-AS1 ( Liu et al, 2019 ; You et al, 2020 ; Lu et al, 2021 ), lncRNA KCNQ1OT1 ( Zhang et al, 2018a ), lncRNA TUG1 ( Yao et al, 2022 ), circARHGAP12 ( Fan et al, 2021 ) and circCDYL2 ( Li et al, 2021 ) ( Table 1 ).…”